Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for allegedly misleading investors regarding its operations and financial performance during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Stride securities from October 22, 2024, to October 28, 2025 [1][2]. - Allegations include inflated enrollment numbers, staffing cuts below statutory limits, non-compliance with requirements, and concealment of enrollment losses [3]. Group 2: Impact on Share Price - The truth about Stride's operations was revealed on September 14, 2025, when a school district sued the company for fraud [4]. - On October 28, 2025, Stride announced that "poor customer experience" led to higher withdrawal rates and fewer enrollments, causing a significant decline in share price [4].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased its securities during the specified Class Period, alleging misleading statements regarding the company's business and operations [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Telix securities from February 21, 2025, to August 28, 2025 [1][2]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Telix - Defendants are accused of making false or misleading statements and failing to disclose that Telix overstated its progress with prostate cancer therapeutic candidates [3]. - The company allegedly exaggerated the quality of its supply chain and partners, leading to misleading statements about its business and prospects [3]. - The complaint claims that when the true state of Telix's business was revealed, investors experienced significant financial losses [3].

Core Viewpoint - Purcell & Lefkowitz LLP is investigating OS Therapies Incorporated to determine if the company's directors breached their fiduciary duties related to recent corporate actions [1]. Group 1 - The investigation is being conducted on behalf of OS Therapies's shareholders [1]. - The law firm specializes in representing shareholders who are victims of securities fraud and breaches of fiduciary duty [3]. - Shareholders interested in their rights and options can contact the firm for more information [2].

Core Viewpoint - The Freeport-McMoRan Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to safety issues at its Grasberg mine in Indonesia, which resulted in significant operational and financial repercussions for the company [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Reed v. Freeport-McMoRan Inc., and it involves purchasers of Freeport-McMoRan securities from February 15, 2022, to September 24, 2025 [1]. - The lawsuit alleges that Freeport-McMoRan and certain executives made false or misleading statements regarding safety measures at the Grasberg Block Cave mine, which heightened risks for workers [3]. - Specific incidents leading to the lawsuit include a significant flow of wet material at the mine on September 9, 2025, which restricted evacuation routes and led to a nearly 6% drop in stock price [4]. Group 2: Incident Impact and Financial Consequences - On September 24, 2025, Freeport-McMoRan reported two fatalities and the ongoing search for five missing team members, resulting in a projected 35% decrease in production for 2026 compared to pre-incident estimates, causing the stock price to fall nearly 17% [5]. - Following a Bloomberg article on September 25, 2025, discussing the potential strain on relations with the Indonesian government due to halted production, the stock price fell more than 6% [6]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Freeport-McMoRan securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [7]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [8].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6]. - Additional impairment charges may be recognized in Q4 2025, ranging from $0 to $685 million [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Integer Holdings Corporation designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company has been accused of overstating demand for its electrophysiology devices while publicly claiming strong sales growth [4][5]. Group 3: Stock Performance and Financial Guidance - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower adoption than anticipated [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - Firefly Aerospace Inc. is facing a class action lawsuit due to alleged violations of securities laws related to its initial public offering (IPO) and subsequent financial disclosures, which reportedly misrepresented the company's operational readiness and growth prospects [1][3]. Company Overview - Firefly Aerospace operates in the space and defense technology sector, providing mission solutions for national security, government, and commercial customers [2]. Class Action Details - The class action lawsuit, titled Diamond v. Firefly Aerospace Inc., claims that during the class period from August 7, 2025, to September 29, 2025, the company and its executives made false or misleading statements regarding the demand for its Spacecraft Solutions and the viability of its Alpha rocket program [1][3]. - The lawsuit alleges that Firefly Aerospace conducted its IPO on August 7, 2025, issuing approximately 19.3 million shares at an offering price of $45.00 per share [2]. Financial Performance - On September 22, 2025, Firefly Aerospace reported a loss of $80.3 million for Q2 2025, compared to a loss of $58.7 million in Q2 2024. Revenue was reported at $15.55 million, which was below analyst estimates of $17.25 million and represented a 26.2% decline year-over-year [4]. - The revenue from the Spacecraft Solutions segment was particularly concerning, with a reported figure of only $9.2 million, indicating a 49% year-over-year decrease [4]. Stock Price Impact - Following the negative earnings report, Firefly Aerospace's stock price fell by more than 15% [4]. - On September 29, 2025, the company disclosed an issue with the first stage of its Alpha Flight 7 rocket, leading to a further decline in stock price of over 20% [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Coupang, Inc. securities between August 6, 2025, and December 16, 2025, of the upcoming lead plaintiff deadline for a securities class action lawsuit set for February 17, 2026 [1]. Group 1: Class Action Details - Investors who bought Coupang securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by February 17, 2026, representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Coupang made false and misleading statements regarding its cybersecurity protocols, which allowed unauthorized access to sensitive customer information for nearly six months [5]. - It is claimed that this breach heightened the risk of regulatory scrutiny and that Coupang failed to report the incident in compliance with SEC regulations, leading to materially false public statements [5].

Core Viewpoint - A securities class action lawsuit has been filed against Bitdeer Technologies Group for allegedly making materially false and misleading statements regarding its business operations and prospects during the class period from June 6, 2024, to November 10, 2025 [1][2]. Allegations Against Defendants - The complaint claims that Bitdeer misrepresented issues related to the SEAL04 chip design, which caused production delays [2]. - Bitdeer allegedly adopted a "dual-track approach" to create two independent designs to compensate for lost progress, while still assuring the public that production timelines were on track [2]. - As a result of these actions, the statements made by the defendants about the company's business and operations were deemed materially false and misleading [2]. Lead Plaintiff Process - Investors in Bitdeer have until February 2, 2026, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [3]. - Participation as a lead plaintiff does not affect the ability of other investors to share in any recovery [3].

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company regarding its financial guidance and strategic actions [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Agilon's securities between February 26, 2025, and August 4, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Agilon - The complaint alleges that Agilon made false and misleading statements to the market, particularly regarding its 2026 guidance, which was deemed unrealistic [4]. - The company is accused of overstating the effectiveness of its strategic actions aimed at reducing risk, leading to materially misleading public statements throughout the class period [4]. - As a result of the revelations about Agilon's true situation, investors reportedly suffered financial damages [4].